FEB 20, 2019 02:43 PM PST

Cocktail of Common Antibiotics Fights E. coli Infections

WRITTEN BY: Nouran Amin

Researchers at the Technical University of Denmark are working towards finding new methods for battling antibiotic resistant bacteria. Currently, many disease-causing bacteria retain resistant genes that protect them against antibiotic treatment. One such resistant gene, CTX-M-15, involves encoding the protein--extended spectrum beta-lactamase (ESBL) which leads to resistance in E. coli for urinary tract infections.

Learn more on antibiotic-resistant bacteria:

However, most recently researchers showed that a cocktail of two common antibiotics, mecillinam and cefotaxime, can result in specific multi-resistant E. coli (extended spectrum beta-lactamase, ESBL) sensitive to treatment again. Results of the cocktail antibiotics study was published in Nature and shows that bacteria resistant to mecillinam, were now sensitive to the drug cefotaxime and bacteria that had become resistant to cefotaxime were now sensitive towards mecillinam. These drugs could be administered orally -- as pills, making it easier for doctors to prescribe the already approved drugs to treat multi-drug resistant E. coli (ESBL) infections.

Image Credit: ZMESCIENCE.com

"The results are interesting because we showed that bacteria simply can't survive both drugs. Also, the same gene with only one mutation shows this switch-function. Normally, you will find multiple mutations in multiple resistance genes, controlling different mechanisms," says first-author Carola Rosenkilde, PhD-student at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at Technical University of Denmark (DTU). "We need to take precautionary measures to avoid resistance, because it is very likely that this mutation will occur at some point. By giving both mecillinam and cefotaxime at the same time, the CTX-M-15 mutation works like a switch, and the bacteria become sensitive to treatment again.”

Source: Technical University of Denmark

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Anti-cancer Drug Disguises as Fat
According to a study published in the Journal of the American Chemical Society (JACS), a new drug-delivery system disguises as fat in order to outsmart tum...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Drug Reduces Heart Attacks in Diabetic Patients
Recent results from a clinical trial that evaluated the addition of a drug called ‘ticagrelor’ to aspirin were shown to improve clinical outcom...
OCT 22, 2019
Clinical & Molecular DX
OCT 22, 2019
Muscular Dystrophy Drug by Sarepta Therapeutics: Approval or Rejection by Drug Regulating Authorities?
Duchenne Muscular Dystrophy (DMD is a rare, genetic disorder that hampers muscle movement and is the most common pediatric muscular dystrophy. I...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Re-Evaluating a Popular Heart Failure Drug
A recent study found that the popular heart drug--sacubitril/valsartan—holds positive effects on the structure and function of the failing heart. Spe...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Evolutionary-Busting Cancer Drug
Researchers at the Institute of Cancer Research in London have discovered that a new type of drug that blocks treatment in cancers. The drug works by inhib...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Therapeutic To Treat The Detrimental Effects of Marijuana
As U.S. states continue to legalize the use of marijuana, so is the number of American women using cannabis before becoming pregnant and to treat morning s...
Loading Comments...